difamilast vs Roflumilast (Zoryve)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: PDE4 · full Atopic Dermatitis pipeline

difamilast · Moizerto / Adquey

Marketed by Aurobindo Pharma and partners

Approved in Atopic Dermatitissmall molecule
Partial signal

NCT03908970 · Phase 3 · completed

This was a randomized, triple-blind (participant, investigator, and care provider), placebo-controlled Phase 3 trial in 364 adult patients with atopic dermatitis. The primary endpoint was the IGA responder rate at Week 4, which was met: 38.46% (95% CI 31.36–45.95) for 1% OPA-15406 versus 12.64% (95% CI 8.18–18.36) for placebo. The trial was adequately powered and used a validated clinical disease activity measure.

Next expected readout: December 2026 · NCT07173478 (registry estimate)

Reported efficacy

Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) (met)

Result source: NCT03908970

Roflumilast (Zoryve)

Marketed by Arcutis Biotherapeutics and partners

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT06631170 · Phase 3 · completed

The trial was randomized, fully blinded, and vehicle-controlled with a validated disease-severity measure as its primary endpoint, and roflumilast cream produced significantly more treatment successes than vehicle (31.9% vs 6.7%, P<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2027 · NCT07560618 (registry estimate)

Reported efficacy

Percentage of subjects with vIGA-AD success (Baseline, week 4): Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) (met)

Result source: NCT06631170

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdifamilastRoflumilast (Zoryve)
EASI-75—Not posted · NCT0557194343.2% vs 22%+21.2 vs placebo0.15% cream · wk 4 · n 433NCT04773587
8 other results
  • 42% vs 19.7% 0.15% cream · wk 4 · n 451 · Phase 3 · secondary NCT04773600
  • 39.4% vs 20.6% 0.05% cream · wk 4 · n 436 · Phase 3 · secondary NCT04845620
  • 56.5% vs 31.1% 0.05% · wk 4 · n 46 · Phase 2 · secondary NCT03916081
  • 51.1% vs 31.1% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 17.4% vs 24.4% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 31.1% vs 24.4% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 8.7% vs 2.2% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 2.2% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
IGA 0/1 with 2-point improvement—Not posted · NCT05571943—Not posted · NCT06631170
EASI-90—Not posted · NCT0557194317.4% vs 17.8%−0.4 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • 26.7% vs 17.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 2.2% vs 8.9% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 8.9% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 0% vs 0% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 2.2% vs 0% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
EASI, % change—Not posted · NCT05571943-69.4% vs -55.8%−13.5 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • -72.3% vs -55.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • -54.3% vs -48.5% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • -57.6% vs -48.5% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • -35.8% vs -24.4% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • -34.7% vs -24.4% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

EASI-75

difamilast
—Not posted · NCT05571943
Roflumilast (Zoryve)
43.2% vs 22%+21.2 vs placebo0.15% cream · wk 4 · n 433NCT04773587
8 other results
  • 42% vs 19.7% 0.15% cream · wk 4 · n 451 · Phase 3 · secondary NCT04773600
  • 39.4% vs 20.6% 0.05% cream · wk 4 · n 436 · Phase 3 · secondary NCT04845620
  • 56.5% vs 31.1% 0.05% · wk 4 · n 46 · Phase 2 · secondary NCT03916081
  • 51.1% vs 31.1% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 17.4% vs 24.4% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 31.1% vs 24.4% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 8.7% vs 2.2% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 2.2% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

IGA 0/1 with 2-point improvement

difamilast
—Not posted · NCT05571943
Roflumilast (Zoryve)
—Not posted · NCT06631170

EASI-90

difamilast
—Not posted · NCT05571943
Roflumilast (Zoryve)
17.4% vs 17.8%−0.4 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • 26.7% vs 17.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 2.2% vs 8.9% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 8.9% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 0% vs 0% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 2.2% vs 0% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

EASI, % change

difamilast
—Not posted · NCT05571943
Roflumilast (Zoryve)
-69.4% vs -55.8%−13.5 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • -72.3% vs -55.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • -54.3% vs -48.5% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • -57.6% vs -48.5% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • -35.8% vs -24.4% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • -34.7% vs -24.4% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. difamilast: 8 of 8 rows · Roflumilast (Zoryve): 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdifamilast
Rows use multiple source trials
Roflumilast (Zoryve)
Rows use multiple source trials
BSA
absolute change · percentage points
-3.94% (n=57) vs -0.32% (n=53) placebo @ 4wk0.3%a,b,c
NCT02914548 · Phase 2 · registry result, not featured evidence
show 1 more dose
-3.73% (n=58) vs -0.32% (n=53) placebo @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-4.41% (n=46) vs -4.16% (n=45) placebo @ 4wk0.05%a,b,c
NCT03916081 · Phase 2 · registry result, not featured evidence
show 1 more dose
-5.1% (n=45) vs -4.16% (n=45) placebo @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
EASI
absolute change · score
-4.17 vs -0.08 placebo score @ 4wk1%d,b,c
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10 other source trials
-4.97 vs 0.35 placebo score @ 4wk0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.07 vs 0.35 placebo score @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.21 vs -1.1 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-2 vs -0.51 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-3.19 vs -1.1 placebo score @ 4wk1%
NCT02068352 · Phase 2
-3.07 vs -0.51 placebo score @ 4wk1%
NCT02068352 · Phase 2
-2.32 vs -0.15 placebo score @ 4wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
-3.16 vs -0.15 placebo score @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-5.33 vs 0.56 placebo score @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-5.52 vs 0.56 placebo score @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
-6.03 vs -4.84 placebo score @ 4wk0.05%a,d,b,c
NCT03916081 · Phase 2 · registry result, not featured evidence
show 1 more dose
-6.44 vs -4.84 placebo score @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
IGA 0/1
responder rate · % of participants
38.46% (n=182) vs 12.64% (n=182) placebo @ 4wk1%e,c
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4 other source trials
14.93% (n=67) vs 9.09% (n=66) placebo @ 4wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
22.39% (n=67) vs 9.09% (n=66) placebo @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
37.5% (n=24) vs 8.33% (n=24) placebo @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
40% (n=25) vs 8.33% (n=24) placebo @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
41.5% (n=433) vs 25.2% (n=221) placebo @ 4wk0.15% creame,c
NCT04773587 · Phase 3
Pruritus VAS
absolute change · score
-10.98 vs -7.3 placebo score @ 8wk0.3%a,b,c,f
NCT02068352 · Phase 2
show 3 more doses
-10.01 vs -7.28 placebo score @ 8wk0.3%
NCT02068352 · Phase 2
-20.71 vs -7.3 placebo score @ 8wk1%
NCT02068352 · Phase 2
-20.33 vs -7.28 placebo score @ 8wk1%
NCT02068352 · Phase 2
-3.05 vs -1.5 placebo score @ 2.142857wk0.5%b,c,f
NCT01856764 · Phase 2 · registry result, not featured evidence
Dropout rate
9.3%1%g
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
8.4%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.6%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
24.4%0.3%
NCT02068352 · Phase 2
18.6%1%
NCT02068352 · Phase 2
8.3%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
13.8%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
25.3%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
11.8%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
8.9%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
31.3%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
20.9%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
8.3%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
4%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
6.7%0.15% creamh
NCT04773587 · Phase 3
show 7 more results
9.1%0.15% cream
NCT04773600 · Phase 3
6.2%0.05% cream
NCT04845620 · Phase 3
34.2%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
33.8%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
8.7%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
2.2%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.8%1%g
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
1.2%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.8%0.3%
NCT02068352 · Phase 2
4.7%1%
NCT02068352 · Phase 2
0%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
3.4%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
7.8%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
3.5%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
3.6%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
22.4%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
10.4%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
4.2%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
4%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
—3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
1.4%0.15% creamh
NCT04773587 · Phase 3
show 7 more results
1.8%0.15% cream
NCT04773600 · Phase 3
1.1%0.05% cream
NCT04845620 · Phase 3
2.3%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
4.6%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
2.2%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
—0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Serious AEs
0%1%g
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 19 more results
0%0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.9%0.3%
NCT02068352 · Phase 2
4.7%1%
NCT02068352 · Phase 2
2.4%0.3%
NCT05372653 · Phase 3 · registry result, not featured evidence
3.4%1%
NCT05372653 · Phase 3 · registry result, not featured evidence
1.2%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0.7%0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0%1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
0%0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
0%1%
NCT02914548 · Phase 2 · registry result, not featured evidence
0%0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
0%1%
NCT03018691 · Phase 2 · registry result, not featured evidence
0%0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%0.3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%1% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0%3% ointment
NCT02334787 · Phase 1 · registry result, not featured evidence
0.9%0.15% creamh
NCT04773587 · Phase 3
show 7 more results
0.9%0.15% cream
NCT04773600 · Phase 3
0.2%0.05% cream
NCT04845620 · Phase 3
1.1%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
1.4%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
2.2%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1%g
dermatitis atopic 3.8% (placebo 12.1%)
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 13 more results
0.3%
impetigo 7.2% (placebo 6%)
nasopharyngitis 6% (placebo 3.6%)
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1%
nasopharyngitis 8.2% (placebo 3.6%)
impetigo 2.4% (placebo 6%)
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.3%
dermatitis atopic 26.8% (placebo 21.6%)
nasopharyngitis 7.3% (placebo 8.1%)
pruritus 7.3% (placebo 2.7%)
NCT02068352 · Phase 2
1%
dermatitis atopic 16.3% (placebo 21.6%)
headache 7% (placebo 0%)
nasopharyngitis 2.3% (placebo 8.1%)
NCT02068352 · Phase 2
0.3%
nasopharyngitis 43.9%
dermatitis contact 19.5%
miliaria 12.2%
NCT05372653 · Phase 3 · registry result, not featured evidence
1%
nasopharyngitis 82.8%
gastroenteritis 55.2%
dermatitis diaper 34.5%
NCT05372653 · Phase 3 · registry result, not featured evidence
1% ointment
dermatitis atopic 21.1%
nasopharyngitis 14.5%
folliculitis 6%
NCT03961529 · Phase 3 · registry result, not featured evidence
0.3% ointment
nasopharyngitis 32.6%
dermatitis atopic 20.8%
impetigo 18.1%
NCT03961529 · Phase 3 · registry result, not featured evidence
1% ointment
dermatitis atopic 30.4%
nasopharyngitis 30.4%
conjunctivitis allergic 12.5%
NCT03961529 · Phase 3 · registry result, not featured evidence
0.3%
dermatitis atopic 16.4% (placebo 18.2%)
viral upper respiratory tract infection 10.4% (placebo 10.6%)
pruritus 7.5% (placebo 6.1%)
NCT02914548 · Phase 2 · registry result, not featured evidence
1%
dermatitis atopic 9% (placebo 18.2%)
viral upper respiratory tract infection 6% (placebo 10.6%)
pruritus 1.5% (placebo 6.1%)
NCT02914548 · Phase 2 · registry result, not featured evidence
0.3%
dermatitis atopic 8.3% (placebo 16.7%)
influenza 8.3% (placebo 0%)
upper respiratory tract inflammation 4.2% (placebo 8.3%)
NCT03018691 · Phase 2 · registry result, not featured evidence
1%
upper respiratory tract inflammation 24% (placebo 8.3%)
blood alkaline phosphatase increased 8% (placebo 0%)
dermatitis atopic 4% (placebo 16.7%)
NCT03018691 · Phase 2 · registry result, not featured evidence
0.15%h
covid-19 4.1%
nasopharyngitis 2.7%
upper respiratory tract infection 2.1%
NCT04804605 · Phase 3 · registry result, not featured evidence
show 2 more results
0.15%
covid-19 5.5%
upper respiratory tract infection 5.5%
nasopharyngitis 3.7%
NCT04804605 · Phase 3 · registry result, not featured evidence
0.5%
nasopharyngitis 15% (placebo 0%)
alanine aminotransferase increased 5% (placebo 0%)
application site pain 5% (placebo 5%)
NCT01856764 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 3 versus Phase 2.
  5. ePopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  6. fAssessment timepoints differ: 8 weeks versus 2.142857 weeks.
  7. gPopulation comparability has not been reviewed for 17 of these studies.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

difamilast

Pruritus VRS -0.65 vs -0.04 placebo score @ 4wk1%
absolute change · score
NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 6 more results
-0.8 vs -0.33 placebo score @ 4wk0.3%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.68 vs -0.33 placebo score @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.43 vs -0.06 placebo score @ 0.9285714285714286wk0.3%
NCT02914548 · Phase 2 · registry result, not featured evidence
-0.49 vs -0.06 placebo score @ 0.9285714285714286wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-0.83 vs 0.3 placebo score @ 0.93wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-0.73 vs 0.3 placebo score @ 0.93wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
IGA 44.58% (n=83) vs 18.07% (n=83) placebo @ 4wk0.3%
responder rate · % of participants
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more result
47.06% (n=85) vs 18.07% (n=83) placebo @ 4wk1%
NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA "Treatment Success 14.63% (n=41) vs 2.7% (n=37) placebo @ 4wk0.3%
responder rate · % of participants
Non-responders
NCT02068352 · Phase 2
show 3 more results
20.93% (n=43) vs 2.7% (n=37) placebo @ 4wk1%
Non-responders
NCT02068352 · Phase 2
17.07% (n=41) vs 10.81% (n=37) placebo @ 8wk0.3%
Non-responders
NCT02068352 · Phase 2
16.28% (n=43) vs 10.81% (n=37) placebo @ 8wk1%
Non-responders
NCT02068352 · Phase 2
IGA -0.56 vs -0.09 placebo score @ 4wk0.3%
absolute change · score
NCT02068352 · Phase 2
show 3 more results
-0.55 vs -0.09 placebo score @ 4wk1%
NCT02068352 · Phase 2
-0.54 vs -0.04 placebo score @ 4wk0.3%
NCT02068352 · Phase 2
-0.54 vs -0.04 placebo score @ 4wk1%
NCT02068352 · Phase 2
IGA 0 1 2pt Improvement 56.1% (n=41) @ 4wk0.3%
responder rate · % of participants
No placebo or comparator arm
NCT05372653 · Phase 3 · registry result, not featured evidence
EASI-75 82.93% (n=41) @ 4wk0.3%
responder rate · % of participants
No placebo or comparator arm
NCT05372653 · Phase 3 · registry result, not featured evidence
show 3 more results
55.42% (n=166) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
77.08% (n=144) @ 52wk0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
64.29% (n=56) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
IGA 0/1 34.94% (n=166) @ 52wk1% ointment
responder rate · % of participants
No placebo or comparator arm
NCT03961529 · Phase 3 · registry result, not featured evidence
show 2 more results
52.78% (n=144) @ 52wk0.3% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
51.79% (n=56) @ 52wk1% ointment
NCT03961529 · Phase 3 · registry result, not featured evidence
Pruritus VAS -6.76 vs 0.9 placebo mm @ 4wk0.3%
absolute change · mm
NCT02914548 · Phase 2 · registry result, not featured evidence
show 3 more results
-6.28 vs 0.9 placebo mm @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-18 vs 8.19 placebo mm @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-17.21 vs 8.19 placebo mm @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence
POEM -1.36 vs -0.02 placebo score @ 4wk0.3%
absolute change · score
NCT02914548 · Phase 2 · registry result, not featured evidence
show 3 more results
-2.9 vs -0.02 placebo score @ 4wk1%
NCT02914548 · Phase 2 · registry result, not featured evidence
-4.33 vs 2.26 placebo score @ 4wk0.3%
NCT03018691 · Phase 2 · registry result, not featured evidence
-4.37 vs 2.26 placebo score @ 4wk1%
NCT03018691 · Phase 2 · registry result, not featured evidence

Roflumilast (Zoryve)

vIGA-AD 0 1 32% (n=433) vs 15.2% (n=221) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 17 more results
35% (n=328) vs 17.5% (n=164) placebo @ 4wk0.15% cream
NCT04773587 · Phase 3
21.2% (n=433) vs 6.4% (n=221) placebo @ 2wk0.15% cream
NCT04773587 · Phase 3
8.1% (n=433) vs 0.5% (n=221) placebo @ 1wk0.15% cream
NCT04773587 · Phase 3
28.9% (n=451) vs 12% (n=232) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
32.9% (n=342) vs 13.1% (n=179) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
17.7% (n=451) vs 5.3% (n=232) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
5.9% (n=451) vs 3.1% (n=232) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
39% (n=451) vs 16.9% (n=232) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
27.6% (n=451) vs 10.7% (n=232) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
14.2% (n=451) vs 6.2% (n=232) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
25.4% (n=436) vs 10.7% (n=215) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
27.7% (n=333) vs 11% (n=171) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
35.4% (n=436) vs 14.6% (n=215) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
21.2% (n=436) vs 6.8% (n=215) placebo @ 2wk0.05% cream
NCT04845620 · Phase 3
9.4% (n=436) vs 0.9% (n=215) placebo @ 1wk0.05% cream
NCT04845620 · Phase 3
30.4% (n=436) vs 10.6% (n=215) placebo @ 2wk0.05% cream
NCT04845620 · Phase 3
17% (n=436) vs 3.7% (n=215) placebo @ 1wk0.05% cream
NCT04845620 · Phase 3
WI-NRS 4-point Reduction 33.6% (n=278) vs 20.7% (n=135) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 5 more results
23.8% (n=278) vs 9.8% (n=135) placebo @ 2wk0.15% cream
NCT04773587 · Phase 3
9.5% (n=278) vs 2.3% (n=135) placebo @ 1wk0.15% cream
NCT04773587 · Phase 3
30.2% (n=264) vs 12.4% (n=136) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
22.3% (n=264) vs 6.9% (n=136) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
11.2% (n=264) vs 1.6% (n=136) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
EASI-75 43.2% (n=433) vs 22% (n=221) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 8 more results
42% (n=451) vs 19.7% (n=232) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
39.4% (n=436) vs 20.6% (n=215) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
8.7% (n=46) vs 2.2% (n=45) placebo @ 1wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
13.3% (n=45) vs 2.2% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
17.4% (n=46) vs 24.4% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
31.1% (n=45) vs 24.4% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
56.5% (n=46) vs 31.1% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
51.1% (n=45) vs 31.1% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
vIGA-AD 0 1 40.1% (n=439) @ 4wk0.15%
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 19 more results
35.7% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
42.2% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
36.9% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
48.2% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
46.3% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
45.5% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
49.6% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
47.9% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
45% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
30.8% (n=439) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
7.8% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
33.7% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
15.8% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
39.7% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
21.6% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
37.4% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
23.5% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
42.7% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
24.2% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
WI-NRS -2.1 score @ 4wk0.15%
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 9 more results
-0.3 score @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.4 score @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.2 score @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.7 score @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.8 score @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.6 score @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.3 score @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-3.2 score @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-1.2 score @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
EASI -63.23% (n=439) @ 4wk0.15%
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 9 more results
-36.93% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-68.39% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-17.95% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-72.81% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-33.34% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-73.81% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-39.2% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-74.57% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-27.94% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
EASI -35.77% (n=46) vs -24.39% (n=45) placebo @ 1wk0.05%
percent change · % of baseline
NCT03916081 · Phase 2 · registry result, not featured evidence
show 5 more results
-34.67% (n=45) vs -24.39% (n=45) placebo @ 1wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-54.3% (n=46) vs -48.48% (n=45) placebo @ 2wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-57.65% (n=45) vs -48.48% (n=45) placebo @ 2wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-69.37% (n=46) vs -55.84% (n=45) placebo @ 4wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-72.32% (n=45) vs -55.84% (n=45) placebo @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
EASI-50 30.4% (n=46) vs 22.2% (n=45) placebo @ 1wk0.05%
responder rate · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
show 5 more results
24.4% (n=45) vs 22.2% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
58.7% (n=46) vs 48.9% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
51.1% (n=45) vs 48.9% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
69.6% (n=46) vs 55.6% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
73.3% (n=45) vs 55.6% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
EASI-90 0% (n=46) vs 0% (n=45) placebo @ 1wk0.05%
responder rate · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 5 more results
2.2% (n=45) vs 0% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
2.2% (n=46) vs 8.9% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
13.3% (n=45) vs 8.9% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
17.4% (n=46) vs 17.8% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
26.7% (n=45) vs 17.8% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
EASI 100 0% (n=46) vs 0% (n=45) placebo @ 1wk0.05%
responder rate · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 5 more results
0% (n=45) vs 0% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
2.2% (n=46) vs 0% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
4.4% (n=45) vs 0% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
2.2% (n=46) vs 2.2% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
11.1% (n=45) vs 2.2% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
WI-NRS -2.21 vs -1.7 placebo score @ 1wk0.05%
absolute change · score
NCT03916081 · Phase 2 · registry result, not featured evidence
show 5 more results
-2.46 vs -1.7 placebo score @ 1wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-2.46 vs -2.04 placebo score @ 2wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-2.76 vs -2.04 placebo score @ 2wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-3.34 vs -2.73 placebo score @ 4wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-3.23 vs -2.73 placebo score @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
WI-NRS 4 Improvement 23.9% (n=46) vs 20% (n=45) placebo @ 1wk0.05%
event count · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
show 5 more results
33.3% (n=45) vs 20% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
21.7% (n=46) vs 35.6% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
33.3% (n=45) vs 35.6% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
45.7% (n=46) vs 40% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
37.8% (n=45) vs 40% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: difamilast's landscape · Roflumilast (Zoryve)'s landscape